74713-59-0
74713-59-0 結構式
基本信息
C8 CERAMIDE
C8 CERAMINE, D-ERYTHRO
C8-D-ERYTHRO-CERAMIDE
CERAMIDE C8
D-ERYTHRO-SPHINGOSINE, N-OCTANOYL-
N-OCTANOYL-D-ERYTHRO-SPHINGOSINE
N-OCTANOYL-D-SPHINGOSINE
N-OCTANOYLSPHINGOSINE
N-OCTANOYLSPHINGOSINE, D-ERYTHRO
D-erythro-N-Octanoylsphingosine
N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]Octanamide
N-Octanoyl-C18-sphingosine
N-Octanoyl-D-erythr
Octanamide, N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-, [R-[R*,S*-(E)]]-
N-Octanoyl-D-erythro-sp
N-OCTANOYL-D-ERYTHRO-SPHINGOSINE, 99+%, SYNTHETICAL
N-Octanoyl-D-erythro-sphingosine, synthetical
物理化學性質
常見問題列表
|
PKC
|
apoptosis
|
autophagy
|
C8-ceramide (3 μM; 48 hours) irreversibly reduces tumor-cell proliferation and induces morphological changes.
C8-ceramide can induce necrosis-like cell death, but does not induce caspase-dependent cleavage of PARP (biochemical marker of apoptosis) in human cervical tumor cells.
C8-ceramide may increase the endogenous ROS level (10-30 μM; 24 hours) by regulating the switch of SOD1 and SOD2, causing the anti-proliferation (10-50 μM; 24 hours), and consequently triggering the apoptosis (10-50 μM; 48 hours) of NSCLC H1299 cells.
Cell Viability Assay
| Cell Line: | CALO cells, INBL cells, HeLa cells |
| Concentration: | 3 μM |
| Incubation Time: | 48 hours |
| Result: | Markedly reduced the tumor cell number. |
Cell Proliferation Assay
| Cell Line: | H1299 cells |
| Concentration: | 10 μM, 20 μM, 30 μM, 40 μM, 50 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased the rate of cellular proliferation in a dose-dependent manner, with an IC 50 of 22.9 μM. |
Cell Cycle Analysis
| Cell Line: | H1299 cells |
| Concentration: | 10 μM, 20 μM, 30 μM, 40 μM, 50 μM |
| Incubation Time: | 24 hours |
| Result: | Caused the G1 arrest. |
Apoptosis Analysis
| Cell Line: | H1299 cells |
| Concentration: | 10 μM, 20 μM, 30 μM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Increased the level of cleaved caspase-3. |
C8-ceramide (0.1 mg/kg; intranasal administration) induces more robust CD8
+
and CD4
+
T cell responses to viral infections in virus infected mice.
| Animal Model: | C57BL/6 mice, with lymphocytic choriomeningitis virus infected |
| Dosage: | 0.1 mg/kg |
| Administration: | Intranasal administration |
| Result: | Increased the CD8 + T cell response to influenza in the lungs. |